{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:20:29Z","timestamp":1791602429915,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4158\/ep151172.or","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T15:35:34Z","timestamp":1464017734000},"page":"1068-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Evaluation of Lanreotide Depot\/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1016","volume":"22","author":[{"given":"Aaron I.","family":"Vinik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Wolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilani","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edda","family":"Gomez-Panzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP151172.OR_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.4158\/EP151172.OR_bb0015","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v19.i47.9012","article-title":"Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany","volume":"19","author":"Scher\u00fcbl","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.4158\/EP151172.OR_bb0020","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/annonc\/mdt377","article-title":"Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531)","volume":"24","author":"Mocellin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.4158\/EP151172.OR_bb0025","first-page":"817","article-title":"Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study","volume":"35","author":"Faggiano","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP151172.OR_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical presentation and diagnosis of neuroendocrine tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4158\/EP151172.OR_bb0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4158\/EP14464.DSC","article-title":"AACE\/ACE Disease State Clinical Review: diagnosis and management of midgut carcinoids","volume":"21","author":"Liu","year":"2015","journal-title":"Endocr Pract"},{"key":"10.4158\/EP151172.OR_bb0040","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP151172.OR_bb0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4158\/EP151172.OR_bb0050","unstructured":"SOMATULINE\u00ae DEPOT labeling revision 12\/22\/2014 (reference ID: 3677425). Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022074s010lbl.pdf. Accessed March 9, 2016."},{"key":"10.4158\/EP151172.OR_bb0055","unstructured":"Somatuline\u00ae Autogel\u00ae. Summary of product characteristics (SmPC). Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/25104. Accessed March 9, 2016."},{"key":"10.4158\/EP151172.OR_bb0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP151172.OR_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.4158\/EP151172.OR_bb0070","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: an international, observational study","volume":"48","author":"Ruszniewski","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.4158\/EP151172.OR_bb0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP151172.OR_bb0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP151172.OR_bb0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"Kulke","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.4158\/EP151172.OR_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40262-015-0329-4","article-title":"Population pharmacokinetic analysis of lanreotide autogel\/depot in the treatment of neuroendocrine tumors: pooled analysis of four clinical trials","volume":"55","author":"Buil-Bruna","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.4158\/EP151172.OR_bb0095","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"10.4158\/EP151172.OR_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.4158\/EP151172.OR_bb0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"issue":"suppl 7","key":"10.4158\/EP151172.OR_bb0110","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"\u00d6berg","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041688X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041688X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:01:36Z","timestamp":1761516096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2041688X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"alternative-id":["S1530891X2041688X"],"URL":"https:\/\/doi.org\/10.4158\/ep151172.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Lanreotide Depot\/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP151172.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}